The company's portfolio includes SGT-003, a differentiated gene transfer candidate, for the treatment of Duchenne, AVB-202, a gene transfer candidate for the treatment of Friedreich’s Ataxia, AVB-401 for BAG3 mediated dilated cardiomyopathy, and additional assets for the treatment of undisclosed cardiac diseases.

The neuromuscular and cardiac diseases specialist announced a strategic collaboration with Phlox in January 2023 to target a severe form of genetic dilated cardiomyopathy for which there is currently a significant unmet need for effective treatments.